How to cite item

Personalized chemotherapy in triple-negative breast cancer: are we ready for prime time?

   
@article{SCI24095,
	author = {Romualdo Barroso-Sousa and Geoffrey I. Shapiro and Sara M. Tolaney},
	title = {Personalized chemotherapy in triple-negative breast cancer: are we ready for prime time?},
	journal = {Stem Cell Investigation},
	volume = {6},
	number = {0},
	year = {2019},
	keywords = {},
	abstract = {Triple-negative breast cancer (TNBC) comprises a subgroup of breast tumors characterized by the absence of estrogen- and progesterone-receptor protein expression and human epidermal growth factor receptor-2 (HER2) gene amplification. Approximately 15–20% of all breast tumors are classified as TNBC. Clinically, patients with TNBC have been treated similarly. Because patients with TNBC are not candidates for endocrine or anti-HER2 therapy, chemotherapy remains their most important available systemic therapy and the outcomes are poor compared to other breast cancer subtypes, with median overall survival (OS) reaching fewer than 2 years (1-3).},
	issn = {2313-0792},	url = {https://sci.amegroups.org/article/view/24095}
}